Endocyte, Inc. (NASDAQ:ECYT) VP Christopher P. Leamon sold 5,036 shares of the stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $9.07, for a total transaction of $45,676.52. Following the transaction, the vice president now owns 143,470 shares in the company, valued at $1,301,272.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Endocyte, Inc. (NASDAQ ECYT) traded up $0.63 on Monday, reaching $8.83. 7,629,080 shares of the company’s stock traded hands, compared to its average volume of 1,963,384. The firm has a market capitalization of $541.70, a P/E ratio of -6.95 and a beta of 1.02. Endocyte, Inc. has a 52 week low of $1.17 and a 52 week high of $9.32.
Endocyte (NASDAQ:ECYT) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.02). The firm had revenue of $0.01 million during the quarter. Endocyte had a negative net margin of 78,662.86% and a negative return on equity of 40.33%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the business posted ($0.26) EPS. analysts anticipate that Endocyte, Inc. will post -0.96 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its stake in Endocyte by 46.5% in the fourth quarter. Bank of New York Mellon Corp now owns 51,313 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 16,283 shares in the last quarter. AXA acquired a new stake in Endocyte in the fourth quarter valued at approximately $101,000. Dimensional Fund Advisors LP boosted its stake in Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 25,003 shares in the last quarter. Geode Capital Management LLC boosted its stake in Endocyte by 15.6% in the fourth quarter. Geode Capital Management LLC now owns 241,498 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 32,603 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Endocyte by 42.0% in the fourth quarter. Renaissance Technologies LLC now owns 293,580 shares of the biopharmaceutical company’s stock valued at $1,257,000 after acquiring an additional 86,800 shares in the last quarter. Institutional investors own 41.56% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/03/12/insider-selling-endocyte-inc-ecyt-vp-sells-5036-shares-of-stock.html.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.